ImmuCell Corporation (NASDAQ:ICCC) is scheduled to be releasing its earnings data after the market closes on Monday, August 14th.

ImmuCell Corporation (NASDAQ:ICCC) last issued its quarterly earnings data on Thursday, May 11th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter. The firm had revenue of $3.54 million during the quarter. ImmuCell Corporation had a return on equity of 3.52% and a net margin of 6.34%. On average, analysts expect ImmuCell Corporation to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

In other news, insider Brian L. Pessin purchased 30,000 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was purchased at an average cost of $5.25 per share, with a total value of $157,500.00. Following the purchase, the insider now owns 70,000 shares in the company, valued at approximately $367,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 20.10% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ImmuCell Corporation (ICCC) Scheduled to Post Earnings on Monday” was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/07/immucell-corporation-iccc-scheduled-to-post-earnings-on-monday.html.

Separately, TheStreet raised ImmuCell Corporation from a “c” rating to a “b-” rating in a research note on Monday, June 12th.

ImmuCell Corporation Company Profile

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Earnings History for ImmuCell Corporation (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corporation and related companies with MarketBeat.com's FREE daily email newsletter.